Biotech startups that raised Series B in China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Huasaiboman Medical Cell Biology | Qingdao Shi | Series B | $30.0M | 2026-11-09 |
| Enjosim | Shanghai | Series B | $30.1M | 2026-11-02 |
| Bluesail Surgical | Shanghai | Series B | $104.5M | 2026-09-23 |
| Medefa | Zhuhai | Series B | $14.9M | 2026-09-02 |
| Yuce Biotechnology | Suzhou | Series B | $7.4M | 2026-08-31 |
| Hongxin Biology | Shenzhen | Series B | $14.0M | 2026-08-13 |
| Layerwave Bio | Daxing | Series B | $13.8M | 2026-07-28 |
| MindRank AI | Shanghai | Series B | $52.0M | 2026-07-08 |
8 rows of the CSV in 5 of its 18 columns.
- The 301 biotech startups in China whose last round is Series B have raised $9.1B in total.
- 54 of them closed their most recent round in the last 12 months, $1.3B combined.
- The largest of those rounds is Syneron's $150.0M Series B, dated March 2026.
- The most recent is Huasaiboman Medical Cell Biology's $30.0M Series B on 9 November 2026.
- Qiming Venture Partners is an investor in 7 of them, more than any other fund.
- Health care is the most common other sector, with 261 companies (87%).
- 16% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 11 to 50 employees (31% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
29 of 301| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Huasaiboman Medical Cell Biology | Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. | Biotech | Qingdao Shi | Series B | $30.0M | 2026-11-09 | $30.0M | ASBV | 11 to 50 | 2019 |
| Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Shanghai | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital | 51 to 100 | 2021 |
| Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| Medefa | Medefa uses synthetic biology to mass-produce novel PHA biomaterials. | Biotech | Zhuhai | Series B | $14.9M | 2026-09-02 | $16.3M | Motianshi Touzi, Taiping Innovation | 11 to 50 | 2019 |
| Yuce Biotechnology | Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. | Biotech | Suzhou | Series B | $7.4M | 2026-08-31 | $22.4M | Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 | 101 to 250 | 2019 |
| Hongxin Biology | Hongxin Biology develops mRNA drugs and delivers nucleic acid therapeutics to patients. | Biotech | Shenzhen | Series B | $14.0M | 2026-08-13 | $14.0M | Haiyuan Capital, Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group | 11 to 50 | 2021 |
| Layerwave Bio | Layerwave Bio develops diagnostic instrument reagents and biomedical research instruments. | Biotech | Daxing | Series B | $13.8M | 2026-07-28 | $13.8M | IDG Capital, Addor Capital, Hotung Venture Capital | 51 to 100 | 2020 |
| MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Shanghai | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| ThunderBio Innovation | ThunderBio Innovation produces microfluidic chips, instruments, and reagents for laboratory applications. | Biotech | Jiaxing | Series B | $17.7M | 2026-06-15 | $34.6M | Lucion, Guangzhou Financial Holding Fund Management, Zhuopu Touzi | 11 to 50 | 2018 |
| HemaCell | HemaCell develops cell therapies that regenerate hematopoietic lineages in vitro through stem cell reprogramming. | Biotech | Suzhou | Series B | $14.8M | 2026-06-02 | $62.0M | Northern Light Venture Capital, CDH Investments, CMB International Capital Corporation | 1 to 10 | 2021 |
| Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Shanghai | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| Novamab | Novamab researches and develops new nanobodies. | Biotech | Shanghai | Series B | $43.9M | 2026-04-24 | $97.8M | Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 | 51 to 100 | 2017 |
| CSR Biotech | CSR Biotech provides cell imaging and data processing services for biological research. | Biotech | Haidian | Series B | $45.0M | 2026-03-10 | $45.0M | Qiming Venture Partners | 51 to 100 | 2019 |
| Findcure | Findcure develops anti-cancer medications through drug discovery and development. | Biotech | Daxing | Series B | $14.5M | 2026-02-14 | $14.5M | Hecheng Capital, Renxi Fund, Yishang Huicheng Investments | 11 to 50 | 2019 |
| Transcend Vivoscope | Transcend Vivoscope is a biotechnology company that offers advanced microscopy imaging products and solutions. | Biotech | Haidian | Series B | $14.5M | 2026-02-10 | $14.5M | China Capital Management, Zefu Innovation, Guangzhou Tongxin Science and Technology Innovation Fund | 11 to 50 | 2016 |
| Alioth | Alioth develops and applies technical products for pharmaceutical process technology. | Biotech | Shanghai | Series B | $14.4M | 2026-01-15 | $54.7M | Matrix Partners China, Legend Capital | 51 to 100 | 2021 |
| Anlong Bio | Anlong Bio researches and develops nucleic acid drugs, including gene therapy, RNA drugs, and gene editing. | Biotech | Beijing | Series B | $14.3M | 2026-01-07 | $14.3M | TaiKun Fund | 51 to 100 | 2019 |
| D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| Rigen Biotech | Rigen Biotech provides molecular diagnosis of thyroid tumors. | Biotech | Minhang | Series B | $14.1M | 2025-11-28 | $29.8M | BioTrack Capital, Boyuan Capital, Guotai Junan Innovation Investment +1 | 101 to 250 | 2017 |
| Alpha Biopharma | Alpha Biopharma is a clinical-stage biopharmaceutical company. | Biotech | Huangpu | Series B | $23.9M | 2024-06-22 | Qiming Venture Partners, TF Capital, LYZZ Capital | 51 to 100 | 2017 | |
| CureGenetics | CureGenetics develops medicines and molecular diagnostics for cancers and genetic diseases. | Biotech | Suzhou | Series B | $9.0M | 2024-03-28 | Qiming Venture Partners, Oriza Holdings, Qingsong Fund +1 | 51 to 100 | 2016 | |
| Hengyu Biotechnology | Hengyu Biotechnology provides biosafety testing and process validation through a CXO platform. | Biotech | Jiaxing | Series B | $27.8M | 2024-03-11 | CMB International Capital Corporation, GP Capital, Haibang Capital +2 | 101 to 250 | 2020 | |
| Precedo Biomedical | Precedo Biomedical specializes in industrial safety and national strategic biosafety. | Biotech | Hefei | Series B | $13.8M | 2023-11-14 | Sunland Fund | 101 to 250 | 2015 | |
| Raisecare | Raisecare conducts life science research, sells life science goods, and develops in vitro diagnostic tools. | Biotech | Qingdao Shi | Series B | $13.7M | 2023-11-03 | $13.7M | CICC Capital, CITIC Medical Fund, Chongqing Yinuo | 251 to 500 | 2016 |
| Onechip Bioelectronics | Onechip Bioelectronics develops biosensor chips and nanomaterials. | Biotech | Zhangjiagang | Series B | $13.7M | 2023-09-28 | Matrix Partners China, Qiming Venture Partners, Xiamen C&D Emerging Industry Equity Investment +1 | 11 to 50 | 2014 | |
| Chuangjian Medical | Chuangjian Medical Technology develops, sells, and researches novel protein and nucleic acid-based medicines. | Biotech | Changzhou | Series B | $27.5M | 2023-09-16 | $57.2M | CDH Investments, L Catterton, CDF-Capital +1 | 101 to 250 | 2015 |
| Qihan Biotech | Qihan Biotech develops gene-editing technology for organ transplantation. | Biotech | Hangzhou | Series B | $16.0M | 2023-09-15 | $116.3M | Matrix Partners China, Northern Light Venture Capital, CMB International Capital Corporation +1 | 101 to 250 | 2017 |
| StoneWise | StoneWise builds an intelligent drug discovery platform for pharmaceutical research. | Artificial intelligence | Haidian | Series B | $100.0M | 2021-04-12 | Legend Capital, Luminous Ventures (former Lightspeed China Partners), Hillhouse Ventures +1 | 51 to 100 | 2018 | |
| Crabyter | Crabyter develops a platform for managing clinical scientific research data. | Biotech | Putuo | Series B | $2.9M | 2016-12-07 | $6.5M | PreAngel, Kaitai Capital, Prox Ventures +1 | 101 to 250 | 2013 |
Table 1. Biotech startups that raised Series B in China: the 29 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 301.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| 2 | Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| 3 | Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Shanghai | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| 4 | MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Shanghai | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| 5 | CSR Biotech | CSR Biotech provides cell imaging and data processing services for biological research. | Biotech | Haidian | Series B | $45.0M | 2026-03-10 | $45.0M | Qiming Venture Partners | 51 to 100 | 2019 |
| 6 | Novamab | Novamab researches and develops new nanobodies. | Biotech | Shanghai | Series B | $43.9M | 2026-04-24 | $97.8M | Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 | 51 to 100 | 2017 |
| 7 | Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Shanghai | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital | 51 to 100 | 2021 |
| 8 | Huasaiboman Medical Cell Biology | Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. | Biotech | Qingdao Shi | Series B | $30.0M | 2026-11-09 | $30.0M | ASBV | 11 to 50 | 2019 |
| 9 | ThunderBio Innovation | ThunderBio Innovation produces microfluidic chips, instruments, and reagents for laboratory applications. | Biotech | Jiaxing | Series B | $17.7M | 2026-06-15 | $34.6M | Lucion, Guangzhou Financial Holding Fund Management, Zhuopu Touzi | 11 to 50 | 2018 |
| 10 | Medefa | Medefa uses synthetic biology to mass-produce novel PHA biomaterials. | Biotech | Zhuhai | Series B | $14.9M | 2026-09-02 | $16.3M | Motianshi Touzi, Taiping Innovation | 11 to 50 | 2019 |
Table 2. Biotech startups that raised Series B in China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 7 | 2% | 2 | Novamab, CSR Biotech |
| 2 | CMB International Capital Corporation | Investment bank | Central, Hong Kong | 5 | 2% | 1 | HemaCell |
| 3 | Matrix Partners China | Venture capital firm | Beijing, China | 5 | 2% | 2 | Alioth, D3 Bio |
| 4 | BioTrack Capital | Venture capital firm | Shanghai, China | 4 | 1% | 2 | Yuce Biotechnology, Rigen Biotech |
| 5 | Northern Light Venture Capital | Venture capital firm | Beijing, China | 4 | 1% | 1 | HemaCell |
| 6 | Legend Capital | Venture capital firm | Beijing, China | 4 | 1% | 1 | Alioth |
| 7 | Huagai Capital | Private equity firm | Beijing, China | 3 | 1% | 2 | Bluesail Surgical, MindRank AI |
| 8 | Addor Capital | Venture capital firm | Nanjing, China | 3 | 1% | 1 | Layerwave Bio |
| 9 | IDG Capital | Private equity firm | Beijing, China | 3 | 1% | 1 | Layerwave Bio |
| 10 | GL Ventures LLC | Venture capital firm | Beijing, China | 3 | 1% | 1 | Etern |
| 11 | Gaorong Capital | Venture capital firm | Wangjing, China | 3 | 1% | 1 | Bivision |
| 12 | Lilly Asia Ventures | Venture capital firm | Shanghai, China | 3 | 1% | ||
| 13 | CICC Capital | Private equity firm | Beijing, China | 3 | 1% | ||
| 14 | Hillhouse Ventures | Venture capital firm | Singapore | 3 | 1% | ||
| 15 | Luminous Ventures (former Lightspeed China Partners) | Venture capital firm | Shanghai, China | 2 | 1% | 1 | Enjosim |
Table 3. Biotech startups that raised Series B in China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 261 | 87% | $7.9B |
| Software | 12 | 4% | $560.2M |
| Artificial intelligence | 9 | 3% | $489.2M |
| Hardware | 6 | 2% | $74.9M |
| Energy | 2 | 1% | $816.8M |
| Fintech | 1 | 0% |
Table 4. Biotech startups that raised Series B in China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 301 | 100% | $14.9M |
Table 5. Biotech startups that raised Series B in China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 6. Biotech startups that raised Series B in China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 4 | 7% | $75.0M |
| October 2026 | 1 | 2% | $10.5M |
| September 2026 | 6 | 11% | $221.7M |
| August 2026 | 2 | 4% | $21.5M |
| July 2026 | 4 | 7% | $65.8M |
| June 2026 | 3 | 6% | $32.5M |
| May 2026 | 4 | 7% | $114.8M |
| April 2026 | 4 | 7% | $75.5M |
| March 2026 | 4 | 7% | $230.9M |
| February 2026 | 5 | 9% | $86.7M |
| January 2026 | 8 | 15% | $86.5M |
| December 2025 | 7 | 13% | $216.2M |
| November 2025 | 2 | 4% | $14.1M |
Table 7. Biotech startups that raised Series B in China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 45 | 15% | $1.0B |
| 2025 | 38 | 13% | $627.4M |
| 2024 | 25 | 8% | $330.1M |
| 2023 | 45 | 15% | $806.4M |
| 2022 | 40 | 13% | $1.9B |
| 2021 | 31 | 10% | $1.6B |
Table 8. Biotech startups that raised Series B in China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 48 | 16% |
| 2015 to 2019 | 136 | 45% |
| 2010 to 2014 | 68 | 23% |
| Before 2010 | 48 | 16% |
Table 9. Biotech startups that raised Series B in China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 17 | 6% |
| 11 to 50 | 84 | 31% |
| 51 to 100 | 65 | 24% |
| 101 to 250 | 64 | 24% |
| 251 to 500 | 21 | 8% |
| 501 to 1,000 | 13 | 5% |
| 1,001 to 5,000 | 7 | 3% |
Table 10. Biotech startups that raised Series B in China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series B and its headquarters is in China. On 16 November 2026 that is 301 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 29 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 301 rows: 76 have no round amount, 0 no city and 79 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in China whose last round is Series B are on the list?
- 301, in the file dated 16 November 2026. 54 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 301 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.